Eli Lilly Says New Weight-Loss Drug Cuts Body Weight by Over 30%
Updated
Updated · The Washington Post · May 24
Eli Lilly Says New Weight-Loss Drug Cuts Body Weight by Over 30%
8 articles · Updated · The Washington Post · May 24
More than 30% body-weight loss was reported at the highest dose of Eli Lilly's new GLP-1 obesity drug, a result the company said rivals gastric bypass surgery.
That level of reduction, if confirmed, would mark a major step beyond current weight-loss medicines and broaden treatment options for severe obesity.
GLP-1 drugs are already reshaping obesity care, and Lilly's latest data add to evidence that the class is becoming more potent.
The result also points to wider potential benefits because obesity treatment is increasingly tied to managing other chronic diseases.
With drugs now matching surgical weight loss, are we overlooking the risk of trading fat for weaker bones and muscles?
Could the new $200 billion weight-loss drug market trigger a multi-billion dollar collapse in the food industry?
Retatrutide Achieves 30% Weight Loss in Trials: A Comprehensive Review of Efficacy, Mechanism, and Future Impact on Obesity Treatment
Overview
Retatrutide has shown groundbreaking efficacy in clinical trials, with the TRIUMPH-1 study revealing that participants on the highest dose lost an average of 70.3 pounds (28.3%) over 80 weeks. Nearly half of the participants achieved at least 30% weight loss, a result that rivals bariatric surgery. These impressive findings position retatrutide as a potentially transformative treatment for weight management and suggest it could redefine standards in obesity care. The strong results highlight its promise as a future cornerstone in obesity treatment, pending further regulatory developments.